Skip to content

Biokinetic studies on the impact of formulation on resveratrol bioavailability

Biokinetic studies on the impact of formulation on resveratrol bioavailability - Resveratrol formulation

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
DRKS
Registry ID
DRKS00004311
Enrollment
12
Registered
2012-08-13
Start date
2011-05-02
Completion date
Unknown
Last updated
2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

metabolism of resveratrol in healthy volunteers

Interventions

Group 1: Vineatrol, 0,5 mg resveratrol-equivalents per kg body weight (single oral dose as gelatine capsule) Group 2: resverasorb, 0,5 mg resveratrol-equivalents per kg body weight (single oral dose a

Sponsors

Max Rubner-Institut
Lead Sponsor

Eligibility

Sex/Gender
Male
Age
18 Years to 40 Years

Inclusion criteria

Inclusion criteria: healthy men (18 - 40 Jahre) BMI 20 – 25 kg/m2 non-smoker participants, who gave written informed consent

Exclusion criteria

Exclusion criteria: Subjects with serious diseases related to nutrient absorption, digestion, metabolism and excretion. Subjects who used nutritional supplements or medication within the last three months which might interact with parameters of interest. Subjects that might be non-compliant. Subjects with allergies on the study substance or other ingreedients of the formulation.

Design outcomes

Primary

MeasureTime frame
AUC, Camx, tmax of resveratrol and its metabolites in plasma. Analysis by LC-MS/MS before, 20, 40, 60, 90, 120, 180, 270, 360, 480, 720 min and 24h after intake.

Secondary

MeasureTime frame
Resveratrol and metabolite excretion in urine. Analysis by LC-MS/MS of sample periods 0-4h, 4-8h, 8-12h, and 12-24h.

Countries

Germany

Contacts

Public ContactAnita Kriebel

Max Rubner-Institut

anita.kriebel@mri.bund.de0721 6625413

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Mar 24, 2026